linjc16/ctgov huggingface dataset:
Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

Study Overview
=================
Brief Summary
-----------------
Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

Detailed Description
-----------------
This study is a prospective, open-labelled, monocentric trial. The aim is to observe, in patient with choroidal melanoma (any stage of the disease), the prevalence of the circulating tumor DNA at the diagnostic and its evolution during 3 years. The patient will have a blood sample at the following times : T0: before treatment of the primary tumor. T1: 1 months after the end of the local treatment. T2: at 7 months. Tn: every 6 months up to 3 years.

Official Title
-----------------
Study of Circulating Tumoral DNA Evolution in Plasma in Choroidal Melanoma

Conditions
-----------------
Choroidal Melanoma

Intervention / Treatment
-----------------
* Biological: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years old or more. Patient with a recent choroidal melanoma before the start of the specific treatment. Patient able to stand a blood collection. Work-up for extension (CT). Patient explanation given and consent information signed or by legal representative Exclusion Criteria: Patient without social protection / insurance. Person deprived of liberty or under guardianship. Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blood sampling<br> | Biological: Blood sampling<br>* 3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assesment of the change of the circulating tumor DNA from baseline at 3 years |  | T0: before treatment; T1: 1 month after local treatment; T2: at 7 months; Tn : every 6 months up to 3 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the treatment effects of the primary tumor (protontherapy, iodine plaque, enucleation) on the rate of circulating tumoral DNA. |  | 3 years | 
| Comparison of the circulating tumor DNA rate to hepatic imaging if available. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
circulation tumor DNA, choroidal melanoma
Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the performance of two daily disposable contact lenses in a population of daily disposable contact lens wearers.

Official Title
-----------------
Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Nelfilcon A contact lens
* Device: Narafilcon A contact lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently wearing any spherical daily disposable contact lens except the two study products for at least 3 months prior to enrollment. Currently wearing contact lenses at least 8 hours/day and 5 days/week. Other protocol inclusion/exclusion criteria may apply. Exclusion Criteria: Eye injury or surgery within twelve weeks immediately prior to enrollment. Currently enrolled in any clinical trial. Prior history of corneal or refractive surgery. Monovision correction. Other protocol inclusion/exclusion criteria may apply.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Nelfilcon A / Narafilcon A<br>Nelfilcon A contact lenses, then Narafilcon A contact lenses | Device: Nelfilcon A contact lens<br>* Spherical, soft contact lens for daily disposable wear<br>Device: Narafilcon A contact lens<br>* Spherical, soft contact lens for daily disposable wear<br>|
| Other: Narafilcon A / Nelfilcon A<br>Narafilcon A contact lenses, then Nelfilcon A contact lenses | Device: Nelfilcon A contact lens<br>* Spherical, soft contact lens for daily disposable wear<br>Device: Narafilcon A contact lens<br>* Spherical, soft contact lens for daily disposable wear<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Lens Satisfaction | Overall Lens Satisfaction, as interpreted by the subject and reported by the subject on a questionnaire as a single, retrospective evaluation of 1-week's wear time. Overall lens satisfaction was measured on a 10-point scale, with 1 being poor and 10 being excellent. | After 1 week of wear |
Web-based Genetic Research on Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine how genes and environment affect risk for Parkinson's disease.

Detailed Description
-----------------
23andMe has created a web-based Parkinson's research initiative to understand the genetic associations found between Parkinson's patients' DNA and their disease. To learn more, visit: https://www.23andme.com/pd/. You can participate in this research initiative without leaving home. If you are eligible to participate, we will send you an in-home 23andMe DNA kit at no cost. We will ask you short online surveys (15-20) about your Parkinson's journey, symptoms, and response to treatment. Enrollment is on-going and open to individuals who have been diagnosed with Parkinson's disease and are residents of the U.S. Participants receive access to ancestry information and uninterpreted genetic data. Participants will also receive regular updates on our research efforts and findings.

Official Title
-----------------
Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of Parkinson's disease by a physician Exclusion Criteria: diagnoses other than Parkinson's, including: progressive supranuclear palsy (PSP) multiple system atrophy (MSA) Shy-Drager syndrome spinal cerebella ataxia (SCA) atypical parkinsonism parkinsonism due to medications, drug-induced parkinsonism vascular parkinsonism frontotemporal dementia with parkinsonism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson's disease patients<br>People diagnosed with Parkinson's disease by a physician | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Saliva DNA test and online surveys with questions about Parkinson's disease experience, symptoms and response to treatment | We want to learn how genes and environment could play role in Parkinson's disease risk and progression | Intermittent surveys every 6 months for up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's, genetic, online, GWAS, genome wide association
Diaphragmatic Function in Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
Animal studies showed that controlled mechanical ventilation (CMV) can induce dysfunction of the diaphragm, resulting in an early-onset and progressive decrease in diaphragmatic force-generating capacity, called ventilator-induced diaphragmatic dysfunction (VIDD).

Official Title
-----------------
Ventilator-Induced Diaphragmatic Dysfunction (VIDD) in Critically Ill Patients

Conditions
-----------------
Critically Ill

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Invasive mechanical ventilation (tracheally intubated or tracheotomized) less than 48h.· Duration of mechanical ventilation for at least 72h.· Subject itself or its next of kin has given written informed consent Exclusion Criteria: Patient is less than 18 years or more than 85 years of age· The attending physician refuses to allow enrollment· The patient refuses informed consent Next of kin is unavailable or refuses informed consent· Pregnant or breast-feeding female. A pregnancy test will be performed in all female patients less than 60 years of age.· Any contraindication to use cervical magnetic stimulation (mechanical cardiac assist device …).· Presence or suspicion of prior diaphragm injury or chronic disease· Presence or suspicion of a central nervous system (CNS) disorder, including (but not limited to): CNS infarction, bleeding, tumor, or infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory function parameters |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mechanical ventilation, Ventilator induced diaphragmatic dysfunction, Weaning, Neuromuscular diseases- Respiratory function tests, Intubated patients in intensive care unit
Nutritional Intervention During Gestation and Offspring Health

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the potential effects of a modified carbohydrate nutritional product for obese pregnant women to reduce maternal glycemia.

Official Title
-----------------
NIGO Health- Nutritional Intervention During Gestation and Offspring Health

Conditions
-----------------
Maternal Glycemia

Intervention / Treatment
-----------------
* Other: Nutritional Supplement
* Other: Standard of Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntarily signed and dated an ICF, approved by an IEC/IRB and provided applicable privacy authorization prior to any participation in the study. Obese (BMI ≥ 30) as determined by pre-pregnancy BMI. ≥18 years of age. ≥15+0 but ≤16+6 weeks gestation with a singleton pregnancy. Willing to follow supplementation protocol and follow appropriate nutritional guidance and refrain from consuming other caloric nutritional supplements that are not approved by the study staff, if applicable. Willing to provide body composition measures on infant at birth. Willing to consider additional measures if follow-up studies are conducted. Exclusion Criteria: Adverse maternal and/or fetal medical history which is expected to alter blood glucose regulations. Previously diagnosed diabetes, previous gestational diabetes, systemic lupus erythematodes, anti-phospholipid syndrome, known renal disease, treated hypertension, uncontrolled hypothyroidism and/or cancer. Taking medications that can impact blood glucose. Previous bariatric surgery. Lactose intolerant and/or has milk protein allergy or requires a special diet regime. Participating in another clinical trial that would impact participation in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nutritional Supplement<br>One 237 ml oral supplement consumed two times a day; Not commercially available. | Other: Nutritional Supplement<br>* Modified carbohydrate<br>|
| Other: Standard of Care<br>As determined by the study site | Other: Standard of Care<br>* As determined by the study site<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal Oral Glucose Tolerance Test (OGTT) | 2 hour OGTT | 27-28 weeks gestation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neonatal Body Composition |  | Birth - 72 hours | 
| Maternal Fasting Blood Glucose |  | 34-36 weeks gestation |
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

Study Overview
=================
Brief Summary
-----------------
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Official Title
-----------------
Observational Retrospective Cohort Study in Patients With Relapsed Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated With Olaparib Following Response to Platinium-based Chemotherapy

Conditions
-----------------
Relapsed Ovarian Cancers Patients

Intervention / Treatment
-----------------
* Drug: Olaparib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be female ≥18 years of age Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy Patients can be either alive or deceased at the time of medical record abstraction Patients should not have any objection that anonymized data will be collected and subjected to automated processing. Exclusion Criteria: Patient that were given olaparib within a clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival (PFS) | PFS (days) = date of progression - date of treatment start + 1 | through study completion, an average of 1 year | 
| overall Survival (OS) | OS (days) = date of death - date of treatment start + 1 | through study completion, an average of 1 year | 
| incidence of events of clinical interest | the following events: anemia, thrombopenia, nausea and vomiting, fatigue, myelodysplastic syndrome, upper respiratory infections, diarrhea, decreased appetite, dysgeusia and headache will be formally retrieved from the source documents. | through study completion, an average of 1 year |
Pain Intensity After Root Canal Instrumentation

Study Overview
=================
Brief Summary
-----------------
Assess the pain intensity in a two visit treatment of molars with irreversible pulpitis after instrumentation with two rotary systems Mpro and Hyflex files.

Official Title
-----------------
Assessment of Pain Intensity After Instrumentation by MPRo and Hyflex Rotatry Files in Molars With Irreversible Pulpitis

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Device: mechanical preparation of root canal system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mandibular molars with acute pulpitis Exclusion Criteria: badly decayed non-restorable molars medically compromised patients

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: M-pro<br> | Device: mechanical preparation of root canal system<br>* Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems<br>|
| Experimental: Hyflex<br> | Device: mechanical preparation of root canal system<br>* Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain felt after mechanical instrumentation in the first visit | using Numeric Rating Scale (NRS) the participant will be asked to verbally rate their pain on a scale from 0 to 10, with 0 equal to no pain and 10 equal to worst possible pain | up to 72 hours |
Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study

Study Overview
=================
Brief Summary
-----------------
Brown adipose tissue (BAT) is unique in its capability to convert chemical energy directly into heat. Active BAT increases energy expenditure and can thereby counteract obesity and insulin resistance. Currently, the imaging method of choice to assess BAT morphology and function is 18F-FDG-PET/CT which is expensive and exposes patients or healthy volunteers to ionizing radiation, thus impeding larger prospective studies. Magnetic resonance imaging (MRI) could constitute a suitable alternative and preliminary small-scale studies are promising. The overall aim of this research proposal is to develop reliable magnetic resonance imaging techniques to facilitate the study of brown adipose tissue in human adults, specifically in the context of endocrine disease. Specifically, investigators want to Develop a reliable MR imaging protocol for human BAT and compare BAT volume to cold induced nonshivering thermogenesis as a measure of BAT activity. Assess the intra-individual variance of BAT volume measured by MRI. Evaluate direct measurement of BAT temperature by functional MRI.

Official Title
-----------------
Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers Age 18-40 years Body mass index (BMI): 17.5-27 kg/m² Exclusion Criteria: known concomitant disease influencing thyroid hormone metabolism severe diseases: chronic heart failure, liver cirrhosis, kidney failure, active cancer known hypersensitivity to cold, e.g. primary or secondary Raynaud's syndrome abuse of alcohol or illicit drugs Women who are pregnant or breast feeding Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant Previous enrolment into the current study implanted device not compatible with MRI, e.g. pace maker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of scBAT volume and cold induced thermogenesis as determined by indirect calorimetry | measurement of scBAT volume and measurement of cold induced thermogenesis as determined by indirect calorimetry, both values measured in a timeframe of two weeks | both measurements within 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brown adipose tissue, magnetic resonance imaging, energy expenditure, non-shivering thermogenesis